JohnCharlesMorrisMD

Professor of Medicine, Co-Director, Comprehensive Lung Cancer Center, Associate Director, UCCI Translational Research and Director, Experimental Therapeutics

Join to view full profile

Dr. Morris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morris' full profile

Already have an account?

Office
234 Goodman Street
Hematology/Oncology
Cincinnati, OH 45219
Phone+1 513-475-8500

Fax+1 513-584-4281

Education & Training

NIH Clinical CenterPost-Doctoral Fellowship, 1995 - 1999
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1986 - 1988
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalChief Residency, Internal Medicine, 1985 - 1986
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1982 - 1985
SUNY Upstate Medical UniversityClass of 1982

Certifications & Licensure

NY State Medical License 1983 - 2024
OH State Medical License 2010 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Corticolimbic Degeneration and Treatment of Dementia Start of enrollment: 2004 Nov 01
Completed
Phase 4
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

162 citations
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
Bryan McIver, M. Regina Castro, John C. Morris, Victor Bernet, Robert C. Smallridge
The Journal of Clinical Endocrinology and Metabolism. 2014-04-29
121 citations
Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia
John C. Morris
Archives of Neurology. 2012-06-01
971 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
Lancet. 2019-01-12

Press Mentions

A Progress Report: Expanding Palliative Care with Project ECHOFebruary 19th, 2019
More Non-Smokers Being Diagnosed with Lung CancerNovember 9th, 2018
Recent Studies Unveil Clues to Using Immunotherapy as Cancer TreatmentJuly 3rd, 2018
Join now to see all